Effects of insulin-like growth factor-I and LR3IGF-I on regional blood flow in normal rats.

Gillespie CM, Merkel AL, Martin AA

The Journal of endocrinology1 Nov 1997Cited by 28 (Europe PMC)

PMID9415069DOI10.1677/joe.0.1550351PepBankPUB-09415069

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In normal anaesthetised rats, LR3IGF-I at 125 micrograms/kg/h lowered mean arterial blood pressure by 15% of baseline.
In plain wordsIn rats, LR3IGF-I lowered mean arterial blood pressure by 15% of baseline.
Peptide
IGF-1 LR3
Outcome
DecreaseMean arterial blood pressure, study 1
Study
ratn: not reported in source
normal anaesthetised rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
125 micrograms/kg/h · intravenous · 20 minAs given in this study (rat).
Measurements
MABP decrease from baseline
15%
LR3IGF-I 125 micrograms/kg/h
Source sentences
Summary
with LR3IGF-I also causing a significant decline in MABP (by 15%) at the dose of 125 micrograms/kg/h
2 context sentences(design, population, supporting numbers)
Summary · context
Infusion of IGF-I intravenously, at a dose of 125 micrograms/kg/h, for 20 min
Summary · context
Two studies were conducted to investigate the haemodynamic effects of IGF-I and its analogue LR3IGF-I in normal anaesthetised rats.
Report a problemFND-0941506901
02AnimalAnimal study (in vivo)Efficacy outcome
In normal anaesthetised rats, IGF-I and LR3IGF-I at 125 micrograms/kg/h each lowered mean arterial blood pressure by 25% of baseline over 60 min.
In plain wordsIn rats, a 60-minute infusion of LR3IGF-I lowered mean arterial blood pressure by 25% of baseline.
Peptide
IGF-1 LR3
Outcome
DecreaseMean arterial blood pressure, study 2
Study
ratn: not reported in source
normal anaesthetised rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
125 micrograms/kg/h · intravenous · 60 minAs given in this study (rat).
Measurements
MABP decrease from baseline
25%
IGF-I or LR3IGF-I 125 micrograms/kg/h
Source sentences
Summary
In the second study the intravenous administration of IGF-I or LR3IGF-I, at a dose of 125 micrograms/kg/h, over a period of 60 min, resulted in MABP being significantly lowered by 25% of baseline values.
1 context sentence(design, population, supporting numbers)
Summary · context
Two studies were conducted to investigate the haemodynamic effects of IGF-I and its analogue LR3IGF-I in normal anaesthetised rats.
Report a problemFND-0941506902
03AnimalAnimal study (in vivo)Efficacy outcome
In normal anaesthetised rats, LR3IGF-1 infusion increased blood flow in the gastrocnemius muscle by 308%.
In plain wordsIn rats, LR3IGF-1 infusion raised blood flow in a skeletal muscle by 308%.
Peptide
IGF-1 LR3
Outcome
IncreaseGastrocnemius blood flow
Study
ratn: not reported in source
normal anaesthetised rats
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Measurements
Gastrocnemius blood flow increase
308%
LR3IGF-1
Source sentences
Summary
The gastrocnemius, a representative skeletal muscle, was the only vascular region to show a significant increase in blood flow after IGF-I (by 58%) or LR3IGF-1 (by 308%) infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Two studies were conducted to investigate the haemodynamic effects of IGF-I and its analogue LR3IGF-I in normal anaesthetised rats.
Report a problemFND-0941506903
04AnimalAnimal study (in vivo)Efficacy outcome
In normal anaesthetised rats, blood flow in vascular regions other than the gastrocnemius did not increase significantly after LR3IGF-1 infusion.
In plain wordsIn rats, apart from one skeletal muscle, no other region showed a significant rise in blood flow after LR3IGF-1.
Peptide
IGF-1 LR3
Outcome
No significant changeBlood flow in other vascular regions
Study
ratn: not reported in source
normal anaesthetised rats
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The gastrocnemius, a representative skeletal muscle, was the only vascular region to show a significant increase in blood flow after IGF-I (by 58%) or LR3IGF-1 (by 308%) infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Two studies were conducted to investigate the haemodynamic effects of IGF-I and its analogue LR3IGF-I in normal anaesthetised rats.
Report a problemFND-0941506904
05AnimalAnimal study (in vivo)Efficacy outcome
In normal anaesthetised rats, LR3IGF-I infusion reduced vascular resistance in the brain by 48% compared with vehicle.
In plain wordsIn rats, LR3IGF-I lowered resistance to blood flow in the brain by 48% compared with vehicle.
Peptide
IGF-1 LR3
Outcome
DecreaseBrain vascular resistance
Study
ratn: not reported in source
normal anaesthetised rats
Comparator
Vehicle
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Measurements
Brain vascular resistance reduction
48%
LR3IGF-I
Source sentences
Summary
Vascular resistance in the brain was significantly reduced after infusion of IGF-I (by 60%) or LR3IGF-I (by 48%) as compared with vehicle.
1 context sentence(design, population, supporting numbers)
Summary · context
Two studies were conducted to investigate the haemodynamic effects of IGF-I and its analogue LR3IGF-I in normal anaesthetised rats.
Report a problemFND-0941506905
06AnimalAnimal study (in vivo)Efficacy outcome
In normal anaesthetised rats, LR3IGF-I reduced skeletal muscle vascular resistance by 77% compared with vehicle.
In plain wordsIn rats, LR3IGF-I lowered resistance to blood flow in skeletal muscle by 77% compared with vehicle.
Peptide
IGF-1 LR3
Outcome
DecreaseSkeletal muscle vascular resistance
Study
ratn: not reported in source
normal anaesthetised rats
Comparator
Vehicle
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Measurements
Skeletal muscle vascular resistance reduction
77%
LR3IGF-I
Source sentences
Summary
Skeletal muscle vascular resistance was also reduced by IGF-I (by 41%) and more particularly by LR3IGF-I (by 77%) in comparison to vehicle.
1 context sentence(design, population, supporting numbers)
Summary · context
Two studies were conducted to investigate the haemodynamic effects of IGF-I and its analogue LR3IGF-I in normal anaesthetised rats.
Report a problemFND-0941506906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.